Objective: To examine the effect of zinc supplementation to HIV-1-infected pregnant women on viral load, early mother-tochild transmission of HIV (MTCT), and wasting. Design: Double-blind placebo-controlled randomized clinical trial. Setting: Antenatal clinic in Dar es Salaam, Tanzania. Subjects: Four hundred HIV-1-infected pregnant women. Methods: Women 12-27 weeks of gestation were randomly assigned to receive a daily oral dose of 25 mg zinc or placebo from the day of the first prenatal visit until 6 weeks postdelivery. Weight and mid-upper arm circumference (MUAC) were measured monthly. HIV status of the babies was assessed at birth and at 6 weeks postpartum. Viral load was assessed in a random sample of 100 women at baseline and at the end of the study. Results: Zinc had no effects on maternal viral load or early MTCT. Supplementation was related to a significant threefold increase in the risk of wasting (reaching a MUAC value o22 cm) during an average 22 weeks of observation (RR ¼ 2.7, 95%CI ¼ 1.1, 6.4, P ¼ 0.03), and to a 4 mm decline in MUAC during the second trimester (P ¼ 0.02). Conclusions: Zinc supplementation to HIV-infected pregnant women offers no benefits on viral load or MTCT. The clinical relevance of an apparent decrease in MUAC associated with zinc supplementation is yet to be ascertained. These findings together with the lack of effect on fetal outcomes (reported previously) do not provide support for the addition of zinc supplements to the standard of prenatal care among HIV-infected women.
Introduction
Zinc is an essential micronutrient for immunity. Multiple adverse effects of zinc deficiency have been described at various levels of the immune system, including impairments in lymphopoiesis, T-cell development and performance, thymic function, and humoral responses (Shankar and Prasad, 1998) . Consistently, zinc supplementation has proven efficacious in decreasing child morbidity from diarrheal and respiratory infections (Bhutta et al., 1999 (Bhutta et al., , 2000 .
Among HIV-infected persons, zinc deficiency appears to be a common and severe problem. A number of observational studies have documented low dietary intake of zinc in large percentages of HIV-infected adults (Baum et al., 1994 (Baum et al., , 2003 Tang et al., 1996) . By using zinc plasma concentrations, the prevalence of zinc deficiency among HIV-infected adults has been reported to be as high as 25-50% in some settings (Bogden et al., 1990; Beach et al., 1992; Baum et al., 1995 Baum et al., , 1997b Koch et al., 1996) , and to correlate positively with the stage of disease (Baum et al., 1997b; Bogden et al., 2000) .
The impact of zinc deficiency on HIV-related outcomes has been investigated mostly in observational studies, with varying results. In some studies, low-serum zinc was related to progression to AIDS (Graham et al., 1991) , decreases in CD4 cell counts (Baum et al., 2003) and mortality (Baum et al., 1997a (Baum et al., , 2003 , and low-dietary intake was associated with decreased survival (Baum et al., 2003) . Conversely, another prospective study reported an inverse association between zinc consumption and survival of HIV-positive adults (Tang et al., 1996) . The apparent contradictions in these results could be partly explained by differences in study designs and populations, and by the limitations of observational studies which include residual confounding by unmeasured risk factors, the potential for reverse causality as ill subjects are prone to change their diet, and the fact that zinc plasma concentrations are likely to be influenced by the acute phase response (Brown, 1998) . However, there are also biological mechanisms that could support a dual role of zinc in the course of HIV infection; while zinc has a fundamental impact in sustaining cellular immunity, it is also a necessary element for HIV assembly and infectivity (Ramboarina et al., 2004) .
If zinc has beneficial effects on HIV-related outcomes, supplementation could constitute a helpful inexpensive intervention. Clinical trials on the impact of zinc supplementation among HIV-infected persons are needed to overcome some of the limitations of observational studies conducted to date. Although some trials have included zinc as part of multimicronutrient preparations (Kelly et al., 1999; Jiamton et al., 2003) , only two randomized clinical trials with zinc as a single intervention have been published (Mocchegiani et al., 1995; Bobat et al., 2005) . In one trial of patients receiving zidovudine (Mocchegiani et al., 1995) , daily zinc supplements at three times the recommended dietary allowance (RDA) appeared to avoid weight loss and increased CD4 cell counts after 4 months in a subgroup of patients; however, the design was limited by lack of placebo control and blinding, and a relatively short duration of exposure (1 month). In a randomized, double-blind, placebocontrolled trial among 96 HIV-infected children under 5 years of age, zinc supplementation over a 6-month period appeared to reduce the incidence of watery diarrhea, but had no effect on viral load or CD4 cell counts (Bobat et al., 2005) .
We conducted a randomized, placebo-controlled trial of zinc supplementation among HIV-infected pregnant women from Tanzania, to examine the effects of zinc on pregnancy outcomes and indicators of maternal and child health. We have previously reported that zinc had no effects on fetal survival, duration of pregnancy, birth weight, or maternal CD4 cell counts (Fawzi et al., 2005) ; however, an apparent negative effect was observed on maternal hemoglobin concentrations. In this paper, we present the effects of zinc supplementation on gestational weight gain and wasting, maternal viral load, and early mother-to-child transmission of HIV-1 (MTCT).
Methods

Study design and population
The study was conducted between September 2000 and October 2002, among women who attended prenatal care clinics in Dar es Salaam, Tanzania. Details of the study design have been reported previously (Fawzi et al., 2005) . In brief, 400 HIV-positive women who were 12-27 weeks of gestation, resided in Dar es Salaam at the time of the first interview, and had the intention to stay in the city until delivery and during the postpartum period were randomly assigned to receive a daily oral dose of 25 mg zinc as zinc sulfate or placebo from enrollment until the end of the study, 6 weeks after delivery. This dose is safe for use during pregnancy (Tamura and Goldenberg, 1996) . Both experimental regimens were undistinguishable from each other in taste or appearance. Given the previously reported benefits of daily multivitamin supplementation (Fawzi et al., 1998) , all women received 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 mg B12, 500 mg C, and 30 mg E. Women also received daily ferrous sulfate and folate, and weekly prophylactic chloroquine phosphate. As a measure to prevent MTCT, all women were offered a dose of nevirapine to be taken at the onset of labor, and 2 mg/kg of nevirapine to their infant within 72 h of delivery (Guay et al., 1999) .
Randomization and follow-up visits took place at Muhimbili National Hospital. At the first visit, information on the woman's age, education level, marital status, socioeconomic conditions, and obstetric history was collected. A study physician conducted a complete physical examination and obtained blood specimens that were used for laboratory tests including a complete blood cell count (CBC5 Coulter Counter, Coulter Corporation, Miami, FL, USA), blood smears for malaria, and T-cell subsets count (FACS count system Becton-Dickinson, San Jose, CA, USA). A trained research nurse measured the woman's weight on a calibrated balance beam scale to the nearest 100 g, left mid-upper arm circumference at the midpoint between the olecranon and acromion process with a nonstretchable tape to the nearest 0.1 cm, and height to the nearest 0.1 cm on a standard stadiometer. Additional measurements of weight and MUAC were performed at each of the scheduled monthly follow-up visits to the study clinic until delivery and a last measurement was obtained at the 6 weeks postpartum visit. Women were encouraged to deliver at Muhimbili National Hospital, where full-time research midwives attended to them. Women who did not come for their monthly appointments or who did not deliver at Muhimbili were visited at home when possible and asked to come to the clinic if their condition allowed. In this way, losses of follow-up were kept to a minimum.
At monthly follow-up visits and at delivery, used bottles of regimen were exchanged for new bottles and the remaining pills were counted; a final count was done at the 6 weeks postdelivery visit. We assessed compliance as the number of tablets absent from the returned bottles divided by the total number of tablets the individual should have taken.
Assessment of infant HIV status
For analyses of HIV transmission, we obtained a whole blood sample from the babies at birth and at 6 weeks. We determined HIV-1 status using the Amplicor HIV-1 detection kit version 1.5 (Roche Diagnostic System, Branchburg, NJ, USA).
Determination of maternal viral load
We measured cell-free HIV load in 100 randomly selected women who had blood samples at the first prenatal visit and at the 6 weeks postpartum assessment. This group of 100 women did not differ from the other participants in terms of treatment assignment, socioeconomic characteristics, or CD4 cell counts at baseline. Quantification of cell-free viral load was performed by quantitative competitive reverse transcription polymerase chain reaction (PCR) using the commercially available Roche Amplicor version 1.5 kit.
Data analyses
The effect of zinc on maternal anthropometric outcomes, viral load, and mother-to-child transmission was assessed based on the intent-to-treat principle.
Anthropometry. We examined the effect of zinc on gestational weight gain and MUAC change among women who had a known date of pregnancy outcome, singleton pregnancies, and at least two anthropometric measurements between enrollment and delivery. End points were defined as both continuous and categorical according to the methods described in a previous study (Villamor et al., 2002a) . Continuous end points included total and trimester-specific weight gain (or MUAC change), and the rate of weight gain as the slope from the regression of weight on gestational week. Repeated measures mixed effects models (PROC MIXED; SAS Institute Inc., Cary, NC, USA) with robust estimators of variance (White, 1980) were used in the analyses. In these models, weight or MUAC was the outcome, and treatment, week of gestation, and their interaction term were the predictors (Diggle et al., 2002) . Categorical outcomes were weight loss, defined as an estimated regression slope (rate of weight gain) p0, low weight gain, defined as a regression slope p200 g/week (25th percentile of the distribution of slopes in the population), and wasting, defined as reaching a MUAC value o22 cm (James et al., 1994 , Villamor et al., 2002b ) from recruitment to 6 weeks postpartum, among women with MUAC X22 cm at baseline. Treatment effects on categorical variables were assessed by calculating relative risks with 95% confidence intervals (CI). For the incidence of wasting, we also used a Cox proportional hazards model for time-to-first event.
Viral load. We assessed the effect of zinc on change in maternal viral load from the first prenatal visit to 6 weeks post-delivery using repeated measures ANOVA with treatment assignment, time (baseline or follow-up), and their interaction term as independent variables and log 10 viral load as the outcome. The value corresponding to the lower detection limit of the assay (400 copies/ml) was assigned to samples with undetectable load. Estimating the relative risk and 95% CI, we examined the effect of zinc on high viral load at the last visit, defined as 4100 000 copies/ml.
Mother-to-child transmission HIV status was assessed at birth (range: birth-21 days of life) and at 6 weeks (22-49 days) according to the criteria from a previous trial in this setting (Fawzi et al., 2000) . We defined HIV infection at birth using data from live births whose HIV status was known at birth or who did not have a birth sample but had a negative result at 6 weeks. HIV status at 6 weeks was considered among babies who were known to be negative at birth, and total infection by 6 weeks postpartum was defined as the cumulative incidence up to 6 weeks, which included all available results from birth. We also considered composite outcomes of HIV infection or death by the time of each assessment. Twin pregnancies (n ¼ 10) were considered as single outcomes by assigning the worse outcome of either twin to the pregnancy. For each of these MTCT binary outcomes, the effect of zinc supplements was estimated through relative risks and 95% CI.
In supplemental analyses, we examined whether the effect of zinc on anthropometric and virological outcomes was significantly different within strata of CD4 cell counts, duration of the intervention and, for viral load, baseline viral load and compliance with the nevirapine regimen. The statistical significance of interactions was assessed using the likelihood ratio test. Interactions were not assessed for MTCT due to limited statistical power.
All P-values reported are two-sided; statistical significance in this study is defined as Pp0.05. All statistical analyses were carried out using the SAS system version 8.0 (Cary, NC).
The study protocol was approved by the Research and Publications Committee of Muhimbili University College of Health Sciences, the Ethical Committee of the National AIDS Control Program of the Tanzanian Ministry of Health, and the Institutional Review Board of the Harvard School of Public Health. All participants provided written informed consent to participate in the study.
Results
Characteristics of the study population On average, the participants attended their first prenatal visit at week 23 (s.d. ¼ 4) and were 27 years old (s.d. ¼ 5); 17% percent had CD4 cell counts o200/mm 3 . Baseline characteristics did not differ significantly by treatment arm (Table 1) . Compliance with the study regimen was high between randomization and delivery (mean ¼ 94% s.d. ¼ 10, median ¼ 99%, interquartile range ¼ 93-100%) and between delivery and the end of follow up at 6 weeks postpartum
Full compliance with the nevirapine regimen was also high at 86%.
Maternal anthropometry
Of 400 women randomized, the date of pregnancy outcome could not be determined in four (two in each arm); 10 women had twin pregnancies (three in placebo and seven in zinc), and 10 lacked two anthropometric measurements during pregnancy (two in placebo and eight in zinc). Analyses of weight gain and MUAC change were therefore conducted among 376 participants. Anthropometric follow-up was high; 95% of women attended all their scheduled monthly prenatal visits. There were 1666 visits over an average 14 weeks of observation (s.d. ¼ 4), with a mean 4.5 (s.d. ¼ 1.1) anthropometric measurements per woman; 95% of women had X3 measurements. Availability of anthropometric data was independent of treatment assignment.
Weight gain followed a linear trend in this population, at an average rate of 326 g/week (s.d. ¼ 216); 5% of women lost weight. Zinc supplements had no effect on measures of weight gain during pregnancy, rate of weight gain, or weight loss (Table 2 ). However, supplementation was associated with a significant decrease in MUAC during the second trimester. In time-to-event analyses, zinc was related to a significant 3-fold increased risk of reaching MUAC o22 cm during an average 22 weeks of observation, among mothers whose baseline MUAC was X22 cm (n ¼ 355).
The effects of zinc on anthropometry were not modified by the CD4 cell counts at baseline or by the duration of the intervention.
Viral load
Women selected for viral load analyses (n ¼ 100) did not differ significantly from those not selected in terms of age, parity, education level, socioeconomic indicators, hemoglobin concentration, CD4 cell count, or treatment assignment. The baseline sample was collected at gestation week 22 on average (s.d. ¼ 3) and the follow-up measurement at 6 weeks postpartum (s.d. ¼ 0.9) for a mean 23 weeks between the two samples (s.d. ¼ 5), independent of treatment arm. Log 10 viral load decreased from the baseline to the follow-up measurement in the zinc but not in the placebo group (Table 3) , although the difference in change was not statistically significant. The risk of having high viral load (4100 000 copies/ml) at the postpartum visit was nonsignificantly lower in women who received zinc. There was no evidence of effect modification by baseline CD4 cell counts or viral load, compliance with the nevirapine regimen, or duration of the intervention.
Mother-to-child transmission of HIV HIV status at birth (0-21 days) was known for 286 children, of whom 14 (4.9%) were positive. Among children who were HIV-negative at birth, HIV status at 6 weeks (22-49 days) was known in 183, of whom 12 (6.6%) had become HIV-positive. Zinc supplementation had no significant effects on any of the outcomes related to mother-to-child transmission up to 6 weeks postpartum (Table 4) .
Discussion
In this randomized clinical trial among HIV-1-infected pregnant women, zinc supplements had no effect on gestational weight gain but appeared to increase the risk of wasting as measured by decreased arm circumference. Zinc had no significant effects on maternal viral load or motherto-child transmission of HIV up to 6 weeks postpartum. These results are unlikely due to the influence of confounding factors given the randomized nature of the study. Zinc supplements among HIV-infected women Subject-specific slope of the regression of weight on gestational age p0. f Relative risk (95% CI). g Subject-specific slope of the regression of weight on gestational age p200 g/week. h Mean7s.e. From a repeated-measures, mixed-effects model that included MUAC as the dependent variable, and week of gestation (linear and spline variables), treatment, and interaction terms between treatment and the time variables. 
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The findings need to be interpreted in light of some considerations. All women received other micronutrient supplements that included multivitamins (B-complex, C, and E), iron, and folic acid as per the standard of care in our setting. It has been shown that multivitamins increase weight gain during pregnancy (Villamor et al., 2002a) and reduce viral load (Fawzi et al., 2004) among HIV-infected women; these effects could have reduced the statistical power to observe an effect of zinc alone. Women and newborns were provided prophylactic nevirapine and full compliance was high at 86%; in consequence, the risks of intrapartum transmission as measured by HIV-positive results at 6 weeks among children who tested negative at birth were much lower (6.6%) than those reported in the same setting before nevirapine had become part of antenatal care (15.9%) (Fawzi et al., 2000) . This lower transmission risk could have also decreased power to detect an effect of zinc.
The decrease in arm circumference associated with zinc supplementation was an unexpected finding. Low arm circumference has been validated in epidemiological studies and emergency situations as an indicator of acute wasting (James et al., 1994) and, among HIV-infected African women, it has been identified as an independent predictor of mortality (Lindan et al., 1992) and early MTCT (Zijenah et al., 2004) . In a study in Zimbabwe, the mean difference in MUAC between mothers who transmitted HIV to their babies and those who did not was about 9 mm (Zijenah et al., 2004) , whereas, we found an average negative zinc effect of 4 mm, limited to the second trimester. Whether this decline is clinically relevant as a predictor of mortality or MTCT is yet to be determined.
Zinc supplements did not have an effect on gestational weight gain, which is consistent with their lack of effect on measures of intrauterine growth, that we reported previously (Fawzi et al., 2005) . Owing to this lack of effect on weight gain or fetal growth, it is tempting to speculate that the impact on MUAC represents wasting of maternal body cell mass, rather than wasting of the main components of gestational weight gain, such as fat, fluid, and fetal tissue. An adverse effect of zinc on wasting among HIV-infected women could be explained by a zinc-mediated increase in viral replication, as the HIV nucleocapsid protein has two highly conserved zinc fingers that are fundamental for viral assembly and infectivity (Tanchou et al., 1998; Ramboarina et al., 2004) ; however, in this population, zinc supplementation was not related to increased viral load. Another potential explanation is related to the direct effects of zinc on cellular immunity. Zinc repletion in previously deficient subjects appears to upregulate the production of Th1-systemic cellular host defense proinflammatory cytokines including tumor necrosis factor (TNF)-a (Beck et al., 1997) . In addition, zinc supplementation seems to promote the secretion of leptin (Mantzoros et al., 1998) and in humans, it has been shown that leptin can increase TNF-a and IL-6 production by peripheral blood mononuclear cells and monocytes (Zarkesh-Esfahani et al., 2001) . TNF-a exerts a strong inhibitory effect on myosin expression in muscle cells (Acharyya et al., 2004) and is implicated in the pathophysiology of anorexia; these two mechanisms could lead to wasting.
Previous observational studies found that dietary zinc intake above the recommended dietary allowance (RDA) among HIV-infected persons was related to rapid progression to AIDS (Tang et al., 1993) and mortality (Tang et al., 1996) . In contrast, in a randomized, nonplacebo controlled study of HIV-positive Italian adults who were receiving zidovudine, daily supplementation with three to four times the RDA (45.5 mg zinc) for 1 month appeared to prevent weight loss in patients of advanced stage at baseline, and increased CD4 cell counts after 4 months (Mocchegiani et al., 1995) . Among HIV-1-positive drug users from the United States, dietary zinc intake below 9.3 mg/day was strongly associated with increased risk of death during an average 3.5 years of follow-up (Baum et al., 2003) . In the studies from Italy and the US, the negative associations between zinc status and health outcomes were observed in subjects who were at risk of zinc deficiency. Although we lacked a measurement of the zinc status of women at recruitment in our study, Tanzania is considered to be a country where almost 50% of the population is at risk of inadequate zinc intake (International Zinc Nutrition Consultative Group (IZiNCG), 2004) and it is likely that our study participants were at high risk of zinc deficiency. Yet we did not observe benefits of zinc supplementation.
It is possible that doses different from the ones we used could have effects on outcomes such as viral load; however, the dose in this study (25 mg) was already close to the Tolerable Upper Intake Level for adults (40 mg), and the apparent adverse impact observed on wasting may not support the use of higher doses in future studies of HIVinfected, pregnant women.
In this randomized clinical trial, we found that zinc supplementation to HIV-infected pregnant women from Tanzania was not beneficial in reducing viral load or the risk of early mother-to-child transmission; on the contrary, zinc had the potential to reduce MUAC. These findings, together with the previous report of an apparent negative effect on hemoglobin concentrations and lack of effects on fetal growth and survival (Fawzi et al., 2005) , do not provide support for the inclusion of zinc supplements in prenatal care programs for HIV-infected women. Potential benefits of zinc supplementation to HIV-infected children (Bobat et al., 2005) are to be confirmed in other settings.
